TY - JOUR
T1 - Concomitant therapies as an outcome measure. Part 1: Drugs
AU - Gossec, Laure
AU - Landewé, Robert B. M.
AU - Maillefert, Jean-Francis
AU - Dougados, Maxime
PY - 2005
Y1 - 2005
N2 - Concomitant therapy intake (i.e., drugs other than the study drug) could potentially be used as an outcome measure in therapeutic trials in musculoskeletal disorders. The objective of this Special Interest Group (Part 1) was to investigate this possibility. Concomitant therapy intake could be used as an outcome measure in 2 ways: either as an associated outcome measure if it was determined there was interaction between the study drug and the concomitant drug, or as an outcome measure in itself if concomitant drug intake was deemed important in its own right and fulfilled the OMERACT filter requirement. These 2 aspects were discussed in the session and then put to a vote
AB - Concomitant therapy intake (i.e., drugs other than the study drug) could potentially be used as an outcome measure in therapeutic trials in musculoskeletal disorders. The objective of this Special Interest Group (Part 1) was to investigate this possibility. Concomitant therapy intake could be used as an outcome measure in 2 ways: either as an associated outcome measure if it was determined there was interaction between the study drug and the concomitant drug, or as an outcome measure in itself if concomitant drug intake was deemed important in its own right and fulfilled the OMERACT filter requirement. These 2 aspects were discussed in the session and then put to a vote
M3 - Article
C2 - 16331783
SN - 0315-162X
VL - 32
SP - 2447
EP - 2448
JO - Journal of rheumatology
JF - Journal of rheumatology
IS - 12
ER -